Asthma
|
AGILE Principle Investigator: |
Study A 52-week, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype |
COPD
|
AstraZeneca - COPD Study RESOLUTE D3251C00014 _SitAZ RESOLUTE- Principle Investigator: |
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils e 2804 |
|
SANOFI EFC16819 AERIFY 2 Principle Investigator: |
SANOFI - AERIFY-2 Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of SAR440340 / REGN3500 / ITEPEKIMAB ( anti-IL-33mAb ) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) |
Bronchiectasis
|
The ASPEN Study, INSMED Principle Investigator: |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis |
